Compare · head to head
Ilsung IS vs Reyon Pharmaceutical
Ilsung IS ranks higher overall — 360 rank 59 vs 16.
Ilsung IS leads on Value (51 vs 44), Quality (50 vs 43), Growth (48 vs 42), Safety (50 vs 33) and Sentiment (59 vs 48).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | South Korea | South Korea |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | Small | Small |
| ISIN | KR7003120003 | KR7102460003 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 59 | 16 |
| Value | 51 | 44 |
| Quality | 50 | 43 |
| Growth | 48 | 42 |
| Safety | 50 | 33 |
| Sentiment | 59 | 48 |
| Quality details | ||
| Profitability | 47 | 37 |
| Cash Truth | 53 | 50 |
Ilsung IS vs Kukje PharmaIlsung IS vs Hanall BiopharmaIlsung IS vs Dongwha PharmIlsung IS vs Whanin PharmAdd a third stock →
Full analyses: Ilsung IS · Reyon Pharmaceutical
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100